The scientists of the ADDF’s Aging & Alzheimer's Prevention Program work to advance the research evidence for Alzheimer's prevention therapies. They write peer-reviewed articles and convene leaders at advisory panels and conferences to highlight next steps and tackle the challenges of prevention therapy development.
Hara Y., McKeehan N., Fillit H.M. (2018). Translating the biology of aging into novel therapeutics for Alzheimer disease. Neurology 92(2):84.
Hara Y., McKeehan N., Dacks P.A., Fillit H.M. (2017). Evaluation of the neuroprotective potential of N-acetylcysteine for prevention and treatment of cognitive aging and dementia. Journal of Prevention of Alzheimer's Disease 4(3):201-206.
Dacks P.A. et. al. (2016). A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. Alzheimer's Research & Therapy 8:33.
Geerts H., Dacks P.A., Devanarayan V., Haas M., Khatchaturian Z., et. al. (September 2016); Brain Health Modeling Initiative. From big data to smart data in Alzheimer's disease. The brain health modeling initiative to foster actionable knowledge. Alzheimer's & Dementia 12(9):1014-1021.
Dacks P.A. & Fillit H.M. (May 1, 2016). Recognizing the Spectrum of Cognitive Impairment to Advance Drug Discovery. Journal of the American Medical Directors Association. 17(5):457-458.
Carman A.J., Ferguson R., Cantu R., Comstock R.D., Dacks P.A. et. al. (2015). Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions. Nature Reviews Neurology 11, 230–244.
Carman A.J., Dacks P.A., Lane R.F., & Shineman D.W. (February 2014). Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer’s disease. Journal of Nutrition, Health and Aging. doi. 10.1007/s12603-014-0021-7.
Dacks P.A., Bennett D.A., & Fillit H.M. (2014). Evidence Needs to Be Translated, Whether or Not It Is Complete. JAMA Neurology. 71(2):137-138.
Dacks P.A., Andrieu S., Blacker D., Carman A.J., Green A.M., et. al. (2014). Dementia prevention: optimizing the use of observational data for personal, clinical and public health decision-making. Journal of Prevention of Alzheimer's Disease 1(2):117-123.
Dacks P.A., Shineman D.W., & Fillit H.M. (March 2013). Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease. Journal of Nutrition, Health and Aging. doi. 10.1007/s12603-012-0431-3.
This advisory meeting, hosted by the Alzheimer’s Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD), convened a group of clinical trial experts and biostatisticians to provide insights and recommendations for improving clinical trial designs that will yield meaningful results in phase 2 studies.
This panel brought together leading experts from academia and pharma to discuss opportunities and priorities for drug discovery in Alzheimer’s disease and related dementia, with a focus on vascular and inflammation targets. Panelists discussed priority drug pathways as well as potential drugs that can be repurposed or repositioned for Alzheimer’s disease.
This meeting, held at the New York Academy of Sciences, convened leading scientists to discuss the challenges and opportunities to develop therapies and predictive diagnostics to protect vulnerable patients from cognitive impairment after surgery.
This panel brought together representatives from the American Diabetes Association and American Heart Association in combination with experts from government, academic, and pharmaceutical organizations. Panelists examined opportunities to protect people from dementia and cognitive decline through treatments for existing medical conditions such as diabetes and cardiovascular disease. Panelists discussed the types of research needed to influence clinical practice of common chronic conditions to protect patients at risk of dementia.
This meeting, held at the New York Academy of Sciences, highlighted recent advances in aging biology that represent important opportunities for drug discovery for Alzheimer's and other age-related neurodegenerative diseases, including drug development programs funded by the ADDF.
In partnership with Safe Kids Worldwide and the Andrews Institute for Orthopaedics & Sports Medicine, the ADDF convened an expert advisory panel to identify the gaps in scientific knowledge surrounding the potential link between childhood mild traumatic brain injury (mTBI) and later life cognitive dysfunction and dementia risk.
This meeting, held at the New York Academy of Sciences, explored efforts to derive drugs from natural products, highlighting case studies of compounds at various stages of development for the treatment of Alzheimer’s disease and neurodegeneration.
Leading researchers from academic and government institutes from the United States and Europe came together to discuss the role of research design to advance dementia prevention therapies. Following the panel, the ADDF spearheaded the creation of the Cohorts for Alzheimer’s Prevention Action (CAPA) Consortium, an innovative approach to foster and fund collaboration to accelerate dementia prevention research.